| __timestamp | Amicus Therapeutics, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 2854000000 |
| Thursday, January 1, 2015 | 76943000 | 3014000000 |
| Friday, January 1, 2016 | 104793000 | 5098000000 |
| Sunday, January 1, 2017 | 149310000 | 3734000000 |
| Monday, January 1, 2018 | 270902000 | 5018000000 |
| Tuesday, January 1, 2019 | 286378000 | 9106000000 |
| Wednesday, January 1, 2020 | 308443000 | 5039000000 |
| Friday, January 1, 2021 | 272049000 | 5363000000 |
| Saturday, January 1, 2022 | 276677000 | 4977000000 |
| Sunday, January 1, 2023 | 152381000 | 6923000000 |
| Monday, January 1, 2024 | 5907000000 |
In pursuit of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Gilead Sciences, Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Gilead Sciences consistently allocated substantial resources, with an average annual R&D expenditure of approximately $5.1 billion. This commitment peaked in 2019, with a staggering $9.1 billion, underscoring Gilead's aggressive pursuit of groundbreaking therapies.
In contrast, Amicus Therapeutics, a smaller player, exhibited a more modest yet steadily increasing R&D budget, averaging around $195 million annually. Notably, Amicus's R&D spending surged by over 500% from 2014 to 2020, reflecting its strategic focus on niche therapeutic areas.
These divergent strategies highlight the dynamic nature of biotech R&D, where both scale and focus play pivotal roles in shaping the future of healthcare.
Gilead Sciences, Inc. vs Insmed Incorporated: Strategic Focus on R&D Spending
Comparing Innovation Spending: Gilead Sciences, Inc. and Viatris Inc.
R&D Spending Showdown: Gilead Sciences, Inc. vs Blueprint Medicines Corporation
Research and Development Investment: Gilead Sciences, Inc. vs CymaBay Therapeutics, Inc.
Analyzing R&D Budgets: Gilead Sciences, Inc. vs Supernus Pharmaceuticals, Inc.
R&D Insights: How Teva Pharmaceutical Industries Limited and Amicus Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Amicus Therapeutics, Inc.
Viking Therapeutics, Inc. vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs HUTCHMED (China) Limited
Analyzing R&D Budgets: Amicus Therapeutics, Inc. vs Mesoblast Limited